Latest Period
Q2 2026
Security Snapshot
Kalaris Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KLRS) Institutional Ownership
CUSIP: 482929106
13F Institutional Holders and Ownership History from Q1 2025 to Q2 2026
Institutions Reporting
56
Shares (Excl. Options)
18,035,969
Price
$4.07
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Symbol
- KLRS on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 18,035,969
- Total 13F value
- $73,405,611
- Portfolio coverage rank
- 0%
- Share change
- -542,099
- Value change
- -$4,521,512
- Number of holders
- 56
- Shares outstanding
- 23,801,814
- SEC-reported price per share
- $3.40
- Insider filing price
- $3.40
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- KLRS - Kalaris Therapeutics, Inc. - Common Stock, $0.0001 par value per share is tracked under CUSIP 482929106.
- 56 institutions reported positions in Q2 2026.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 57 to 56 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $107,183,840 to $73,405,611.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 56 institutions filings for Q2 2026.
Security key
482929106
Latest holder period
Q2 2026
13F holders
56
13D/G owners
5
CIK / CUSIP context first
Open Q2 2026 holders
KLRS full holder history
Kalaris Therapeutics, Inc. SEC filings
Kalaris Therapeutics, Inc. company facts
Kalaris Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 482929106:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
5
Security
KLRS
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Samsara BioCapital, L.P. | 54% | -4% | $85,014,842 | -$349,257 | 12,900,583 | -0.41% | Srinivas Akkaraju | 20 May 2026 |
| RTW INVESTMENTS, LP | 5.7% | $12,714,000 | 1,300,000 | RTW Investments, LP | 31 Dec 2025 | |||
| GILEAD SCIENCES, INC. | 3.9% | $4,715,740 | 723,273 | GILEAD SCIENCES, INC. | 18 Mar 2025 | |||
| Invus Global Management, LLC | 1.5% | $754,533 | 282,586 | Invus Public Equities, L.P. | 30 Jun 2025 | |||
| EcoR1 Capital, LLC | 1.1% | $1,315,201 | 201,718 | EcoR1 Capital, LLC | 31 Mar 2025 |
As of 30 Jun 2026, 56 institutional investors reported holding 18,035,969 shares of Kalaris Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KLRS). This represents 76% of the company’s total 23,801,814 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
74%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| SAMSARA BIOCAPITAL, LLC | 54% | 12,881,175 | -0.52% | 4.3% | $52,426,382 |
| RTW INVESTMENTS, LP | 5.5% | 1,300,000 | 0% | 0.05% | $5,291,000 |
| Alyeska Investment Group, L.P. | 2.4% | 572,687 | 0% | 0.01% | $2,330,836 |
| Siren, L.L.C. | 1.8% | 435,798 | 0% | 0.04% | $1,773,698 |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.7% | 398,712 | +56% | 0% | $1,622,758 |
| Ikarian Capital, LLC | 1.5% | 360,000 | 0% | 0.24% | $1,465,201 |
| UBS Group AG | 1.1% | 262,131 | +4139% | 0% | $1,066,873 |
| RENAISSANCE TECHNOLOGIES LLC | 0.63% | 149,351 | +126% | 0% | $607,859 |
| MARSHALL WACE, LLP | 0.58% | 139,201 | +105% | 0% | $566,549 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.48% | 114,037 | +30% | 0% | $464,287 |
| ADAR1 Capital Management, LLC | 0.42% | 100,000 | 0% | 0.02% | $407,000 |
| Woodline Partners LP | 0.42% | 100,000 | 0% | 0% | $407,000 |
| WHI TRUST Co LLC | 0.41% | 97,493 | 0% | 0.26% | $396,797 |
| RAYMOND JAMES FINANCIAL INC | 0.41% | 97,164 | -18% | 0% | $395,457 |
| CITADEL ADVISORS LLC | 0.4% | 95,772 | 0% | $389,792 | |
| BOOTHBAY FUND MANAGEMENT, LLC | 0.39% | 92,261 | 0% | 0.01% | $375,502 |
| Verdad Advisers, LP | 0.34% | 80,297 | 0.31% | $326,809 | |
| MORGAN STANLEY | 0.3% | 72,326 | +89% | 0% | $294,367 |
| VANGUARD FIDUCIARY TRUST CO | 0.28% | 66,179 | +80% | 0% | $269,349 |
| BlackRock, Inc. | 0.23% | 54,442 | +51% | 0% | $221,580 |
| Belpointe Asset Management LLC | 0.17% | 40,000 | 0% | 0.01% | $162,800 |
| Fortis Capital Advisors, LLC | 0.17% | 40,000 | 0% | 0.02% | $162,800 |
| Pale Fire Capital SE | 0.17% | 39,626 | 0.01% | $161,278 | |
| Squarepoint Ops LLC | 0.16% | 38,775 | -2.5% | 0% | $157,814 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.14% | 32,500 | +44% | 0% | $132,275 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
6
Latest
Q2 2026
Rows shown
1-6 of 6
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 18,035,969 | $73,405,611 | -$4,521,512 | $4.07 | 56 |
| 2026 Q1 | 18,578,668 | $107,183,840 | +$2,867,539 | $5.77 | 57 |
| 2025 Q4 | 17,996,162 | $151,883,912 | +$39,427,360 | $8.44 | 51 |
| 2025 Q3 | 13,222,873 | $76,428,251 | +$1,455,559 | $5.78 | 31 |
| 2025 Q2 | 13,362,268 | $35,677,274 | -$2,639,077 | $2.67 | 29 |
| 2025 Q1 | 13,874,350 | $111,411,096 | +$111,410,076 | $8.03 | 31 |